Combination therapy of non-small-cell lung carcinoma

摘要

The result is treatment of non-small cell lung cancer in which the combination with vitamin D derivatives strengthens the therapeutic action of the imatinib tyrosine kinase inhibitor. Composers of a combination of vitamin D analogues, preferably selected from a group including tacalcytol and isomer 5,6-trans calcitriol.